pharma.be’s Post

🌟 Exciting News from the Pharma World! 🌟 Novartis, a trailblazer in innovative #medicines, has become a pioneering industry member of the #UK's health research program, Our Future Health UK. With a generous contribution of £12.5 million, #Novartis is set to fuel research aimed at advancing the prevention, early detection, and treatment of major diseases. This strategic #partnership not only signifies a hefty investment but also opens doors for collaboration with academia and health organizations, enhancing scientific knowledge and accelerating progress in the medical field. Our Future Health, renowned for its commitment to extending healthier lifespans through research, welcomes Novartis Science' expertise and support. The collaboration underscores the #UK's ambition to lead in life sciences, particularly in disease prevention and treatment. Novartis' involvement is a testament to their dedication to enhancing global health outcomes, further evidenced by their recent partnership with Isomorphic Labs in AI-driven drug discovery. Connect, Repost & Follow for more info on the pharmaceutical industry 🌍 #pharma #pharmaceutical #pharmaindustry #europe #pharmaceuticalindustry #healthcare

Pharmaceutical innovations have the potential to reduce the burden of diseases across the world and save lives. However, access to these innovations is not guaranteed for all people who need them, a reality that is reinforcing deeply entrenched global health inequity, especially in low- and middle-income countries #LMICs. Today marks the launch of the Access to Medicine Foundation’s ninth Access to Medicine Index, #ATMI24, which assesses 20 of the world's leading #pharma companies' efforts to expand access to their essential healthcare products - including medicines, vaccines and diagnostics - across LMICs. While progress has been made, #healthequity is still far from realised and companies can do a lot more to make lifesaving products available and affordable everywhere they are needed. Read the #ATMI24 for more on where companies have advanced - and are falling short - in expanding #AccesstoMedicine in LMICs, and the decisive actions they can now take to ensure access is accelerated.

We are thrilled to announce that Market Access Today is officially partnering with the World Evidence, Pricing and Access Congress 2025! Scheduled for March 5-6 at the RAI Congress Centre in Amsterdam, this event is set to be Europe's largest congress in market access, pricing, and evidence, featuring over 250 speakers and welcoming more than 1,500 attendees from the pharmaceutical, biotech, and payer sectors. As we expand the dialogue in healthcare, Market Access Today is proud to stand alongside esteemed solution providers like Valid Insight (part of the Bioscript Group), RxData, Lifescience Dynamics Limited, and Parexel. Together, we'll explore core topics such as Market Access and Pricing, Rare Diseases, and HTA/Payer dynamics, while delving into the latest trends in reimbursement, payment models, and HEOR. We're immensely grateful for the warm congratulations and flattering messages from the event representatives and our community. Your support energizes our commitment to driving innovation and leadership in healthcare. Let's make a transformative impact at the World Evidence, Pricing and Access Congress 2025. Join us as we help shape the future of healthcare. For more information and to register, please visit World Evidence, Pricing and Access Congress 2025: https://lnkd.in/dnbYK3Ft #EPAConf #heor #health #pricing #reimbursement #healtheconomics #healthpolicy #marketaccess #pharmaceuticals #rarediseases #payer 

OutsourcingPharma has covered our latest report on antimicrobial resistance (AMR), highlighting the urgent need for pharmaceutical companies to take decisive action. Despite a few promising antimicrobials in late-stage development, the global race to create effective antibiotics and antifungals is falling short, putting lives at risk. Our latest AMR R&D report from the Access to Medicine Foundation underscores that structured advance planning and investment in access and stewardship are crucial. Projects like GSK’s gepotidacin and Pfizer’s Emblaveo have the potential to save lives, but only if they reach patients swiftly. We need pharmaceutical companies, policymakers, and global health stakeholders to come together and ensure these life-saving drugs are accessible and affordable, particularly for women, children, and those in low- and middle-income countries. The time to act is now. Discover more about our findings and the steps we must take to address this crisis: https://lnkd.in/eucZbR9m #AMR #AntimicrobialResistance #LMICs #DrugResistance #superbugs #AMRStewardship

Our regular column where we select the latest published from September 2024 across the spectrum of #RWE and #HTA. This month, we feature: - Why is the market design for innovative pharmaceuticals not well understood? Francisco Olivença, Jose Diaz, Sreeram Ramagopalan and Lou Garrison Jr - Development of stakeholder-informed recommendations for inclusion of family spillover effects in health technology assessment. David Campbell, Rajshree Pandey, Lisa Bloudek, Josh Carlson, Christopher Wallick, David Veenstra and Stacey Kowal - Analysis of factors associated with use of real-world data in single technology appraisals of cancer drugs by the National Institute for Health and Care Excellence. Jiyeon Kang and John Cairns - Development of a Canadian guidance for reporting real-world evidence for regulatory and health-technology assessment (HTA) decision making. @Mina Tadrous, Theresa Aves, Christine Fahim and colleagues - PMDA Perspective on RWD/RWE Utilization for Regulatory Purposes Including Assessment on the Impacts of Regulatory Actions and Safety Risk of a Drug at Postmarketing Stage. Kazuhiro Kajiyama, Maki Komamine, Naoya Horiuchi, Toyotaka Iguchi, Yoshiaki Uyama - Adopting a framework for rapid real-world data analyses in safety signal assessment. Lu Wang, Negar Golchin, Stephanie von Klot, Claudia A Salinas, Katrin Manlik, Vaishali Patadia, PhD, MBA, MPH, Mary K Miller, Julius Asubonteng, Rachel McDermott, Julie Barberio & Geoffrey Gipson - Examining the effect of missing data and unmeasured confounding on external comparator studies: case studies and simulations. Gerd Rippin, Héctor Sanz, Wilhelmina E Hoogendoorn, Nicolás M Ballarini, Joan A Largent, Eleni Demas, Douwe Postmus, Theodor Framke, Lukas M Aguirre Dávila, Chantal Quinten & Francesco Pignatti - Analytical methods for comparing uncontrolled trials with external controls from real-world data: a systematic literature review and comparison to European regulatory and health technology assessment practice. Milou A Hogervorst, Kanaka V Soman, Helga Gardarsdottir, Wim Goettsch & Lourens T Bloem - Drugs anticipated to be selected for the Medicare Drug Price Negotiation Program in 2025. Emma M Cousin, Sean Sullivan, Ryan N Hansen, Nico Gabriel, Ayuri S Kirihennedige & Inmaculada (Inma) Hernandez Read at The Evidence Base® #heor #healtheconomics #outcomesresearch #rwe #rwd #realworldevidence #realworlddata #marketaccess #pharma #biopharma #medicalaffairs #regulation #regulatoryaffairs #hta #healthtechnologyassessment #healthdata #healthequity #healthpolicy

#euhta update by PD Dr. Michael Hennig and Cencora | Pharma solutions team. I'm at #BIO2024 this week, let me please know if you would like us to discuss what does it mean for your phase III clinical trial and evidence generation plan.

During the past few days, IFPMA delivered several statements representing the innovative pharmaceutical industry at the #WHA77. ◾With the Global Self-Care Federation, Global Medical Technology Alliance (#GMTA), Developing Countries Vaccine Manufacturers Network (DCVMN International), and the Biotechnology Innovation Organization, we stressed the life-sciences industry’s commitment to a pandemic agreement that strengthens the innovation ecosystem and encourages companies to develop the science and tools needed to respond to the next pandemic, while striving for more equitable access. ◾On the Working Group on Amendments to the International Health Regulations (2005) (#WGIHR), we appreciated the substantial collaborative efforts in advancing pandemic preparedness in the IHR text. However, we underscored that the draft still has open issues that may have a counterproductive impact, including unclear terminology. We urge Member States to ensure that technology transfer remains voluntary and on mutually agreed terms. ◾With IGBA - International Generic and Biosimilar medicines Association, Global Diagnostic Imaging, Healthcare IT, and Radiation Therapy Trade Association (#DITTA), Global Self-Care Federation, World Hypertension League, and PATH, we welcomed the WHO’s continued commitment to non-communicable diseases (NCDs). A life-course approach to tackling NCDs is critical given the unsustainable pressures the rising burden of chronic conditions and co-morbidities are placing on healthcare systems worldwide. ◾We have also delivered individual statements welcoming the strategic focus of the 14th General Programme of Work (#GPW14), supporting the WHA’s proposed strategic priorities on #AMR, and commending the resolution on climate change and health.   ➡View and download our positions: https://lnkd.in/eF-6nYCd

On #RareDiseaseDay, we would like to take the chance to highlight our commitment and contribution to improving patient access to orphan drugs in Spain. According to the Spanish Federation of Rare Diseases (#FEDER), there are 3 million people living with #rarediseases in Spain: - 29,37% do not receive any treatment - 17,9% receive inadequate treatment During the last years, Omakase Consulting has worked hard to deliver innovation to patients with rare diseases as early as possible across several therapeutic areas collaborating with key stakeholders (Health Authorities, Decision-makers, Scientific Societies, Patient Associations, Pharmaceutical industry), supporting and promoting equity access among patients. We collaborate to ensure that patients receive treatments reimbursed by the National Health System as soon as possible. Let's continue working together to build a future where all patients receive the treatments they need. #Pharmaceuticals #OrphanDrugs #EquityAccess #MarketAccess #Spain

Weekly Rare Update Partnerships and collaborations across sectors have the potential to create real change in all areas of healthcare, especially in rare diseases. The challenges associated with getting a diagnosis are amplified by NHS constraints, lack of awareness and an unclear diagnosis referral pathway. This ABPI report showcases several partnership examples and provides a simple framework or practical actions to build collaboration and lead to greater innovation in health. For the full report visit The Association of the British Pharmaceutical Industry (ABPI) https://lnkd.in/ekfSrXEY #innovation #collaboration

Pharmaceutical industry updates 💊 In the pharmaceutical frontier, a week can turn the tides of health innovation—and it just did. As we reflect over the last week, it's fair to say advancements in the UK, EU, and US have rekindled our faith in medical progress. The UK set the pace with a revolutionary cancer drug approval. 🇬🇧 The game-changing therapy promises to target previously untreatable forms of the disease. This is not just hope; it's a tangible leap forward for patients entrenched in the fight of their lives. The NHS seems poised to fast-track this breakthrough, aiming to make it accessible, because, let's be honest, innovation without inclusion is no victory at all. Then we shift to the EU where a symphony of collaboration is reshaping Alzheimer's treatment. 🇪🇺 A pan-European consortium has pooled resources to decode one of humanity's most perplexing afflictions, unveiling a drug that could slow cognitive decline. The research hinges on an unprecedented dosage algorithm, personalising treatment like never before. We're seeing the EU's investment in unified health endeavors starting to see success. Across the pond, US biotech giants have joined forces in the war against antibiotic resistance. Leading pharmaceutical companies are sharing antibiotic data to outmaneuver resistant bacteria. This initiative marks a pivotal shift from competition to cooperation, realising that some fights are bigger than any single entity. Remember, behind every capsule, tablet, and injection is an epic tale of human ingenuity. Let's continue to support and advocate for industries and professionals who heal the world daily. 💊🌐✨ #HealthcareHeroes #PharmaInnovations #GlobalHealth